AP
BMY.RT

Arlington Partners’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Arlington Partners’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-89
Closed – – 422
2020
Q4 		$0 Hold
89
– – ﹤0.01% 241
2020
Q3 		$0 Hold
89
– – ﹤0.01% 169
2020
Q2 		$0 Hold
89
– – ﹤0.01% 318
2020
Q1 		$0 Buy
+89
New +$293 ﹤0.01% 384

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Arlington Partners's BMY.RT Position: Q1 2021 in Review

Arlington Partners sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 89 shares.

Arlington Partners first reported a position in BMY.RT in Q1 2020 and held it in 4 quarters. The position peaked at $0 in Q4 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Arlington Partners reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Arlington Partners sold 89 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
  • Arlington Partners first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 4 quarters.
  • Arlington Partners's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $0 in Q4 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Arlington Partners's 13F filing for Q1 2021, filed 19 Apr 2021.